Detalhe da pesquisa
1.
Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP).
Ann Hematol
; 100(2): 429-436, 2021 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-33161453
2.
Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.
Am J Hematol
; 98(8): E204-E208, 2023 08.
Artigo
Inglês
| MEDLINE | ID: mdl-37222267
3.
Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study.
Lancet Oncol
; 16(15): 1506-1514, 2015 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-26404501
4.
Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes.
Br J Haematol
; 168(3): 361-70, 2015 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-25272332
5.
Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Eur J Haematol
; 92(6): 527-36, 2014 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-24580147
6.
Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study.
Ann Hematol
; 92(1): 25-32, 2013 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-22983750
7.
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network.
Front Oncol
; 11: 739171, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34513714
8.
Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: case-control study in patients with multiple myeloma and review of the literature.
Leuk Res
; 31(11): 1487-93, 2007 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-17320951
9.
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
Lancet Haematol
; 4(3): e127-e136, 2017 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-28162984
10.
Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes.
Leuk Res
; 30(4): 385-8, 2006 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-16219350
11.
Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide.
Leuk Res
; 30(3): 283-5, 2006 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-16111749
12.
Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy.
BMJ Support Palliat Care
; 6(1): 80-8, 2016 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-25204541
13.
Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.
Cancer Med
; 4(12): 1789-97, 2015 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-26376955
14.
Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial.
Leuk Lymphoma
; 44(9): 1545-8, 2003 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-14565658
15.
Heterogeneity of response to imatinib-mesylate (glivec) in patients with hypereosinophilic syndrome: implications for dosing and pathogenesis.
Leuk Lymphoma
; 45(6): 1219-22, 2004 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-15360005
16.
Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy.
Leuk Lymphoma
; 54(11): 2458-65, 2013 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-23432724
17.
Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes.
Leuk Res
; 35(4): 504-7, 2011 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-20971509
18.
Non-pegylated liposomal doxorubicin (Myocet®) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma.
Leuk Lymphoma
; 52(7): 1222-9, 2011 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-21612383
19.
Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study.
Leuk Lymphoma
; 52(5): 771-5, 2011 May.
Artigo
Inglês
| MEDLINE | ID: mdl-21299465
20.
Pamidronate for early-stage, untreated myeloma.
J Clin Oncol
; 21(16): 3177-8; author reply 3178, 2003 Aug 15.
Artigo
Inglês
| MEDLINE | ID: mdl-12915612